 Gilead Sciences, Inc. Nasdaq: GILD and Galapagos NV Euronext Nasdaq: GLPG today announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis UC. Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo. Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10. 